ABBV vs LLY
AbbVie Inc. and ELI Lilly & Co., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | ABBV | LLY |
|---|---|---|
| Revenue | $61.2B | $65.2B |
| Net income | $4.2B | $20.6B |
| Gross margin | 70.2% | 83.0% |
| Net margin | 6.9% | 31.7% |
| Return on equity | · | 101.2% |
| Diluted EPS | $2.36 | $22.95 |
| Dividend / share | $6.65 | $6.23 |
| Payout ratio | 275.8% | 26.1% |
| Free cash flow | $17.8B | · |
| Equity | $-3.3B | $26.5B |
| Net debt / equity | · | 1.33× |
| Current ratio | 0.67× | 1.58× |
| Revenue CAGR 5y | 6.0% | 21.6% |
| Profit CAGR 5y | −1.7% | 27.2% |
ABBV and LLY book revenue within 15% of each other, and LLY keeps more of each dollar of revenue as profit (31.7% against 6.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | ABBV | LLY |
|---|---|---|
| FY2025 | $61.2B | $65.2B |
| FY2024 | $56.3B | $45.0B |
| FY2023 | $54.3B | $34.1B |
| FY2022 | $58.1B | $28.5B |
| FY2021 | $56.2B | $28.3B |
| FY2020 | $45.8B | $24.5B |
| FY2019 | $33.3B | $22.3B |
| FY2018 | $32.8B | $21.5B |
| FY2017 | $28.2B | $20.0B |
| FY2016 | $25.6B | $21.2B |
Bottom line
| Fiscal year | ABBV | LLY |
|---|---|---|
| FY2025 | $4.2B | $20.6B |
| FY2024 | $4.3B | $10.6B |
| FY2023 | $4.9B | $5.2B |
| FY2022 | $11.8B | $6.2B |
| FY2021 | $11.5B | $5.6B |
| FY2020 | $4.6B | $6.2B |
| FY2019 | $7.9B | $8.3B |
| FY2018 | $5.7B | $3.2B |
| FY2017 | $5.3B | $-204.1M |
| FY2016 | $6.0B | $2.7B |
15 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −$4,019,000,000 | LLY |
| FY2024 | +$11,291,000,000 | ABBV |
| FY2023 | +$20,194,000,000 | ABBV |
| FY2022 | +$29,512,600,000 | ABBV |
| FY2021 | +$27,878,600,000 | ABBV |
| FY2020 | +$21,264,200,000 | ABBV |
| FY2019 | +$10,946,500,000 | ABBV |
| FY2018 | +$11,259,700,000 | ABBV |
| FY2017 | +$8,242,200,000 | ABBV |
| FY2016 | +$4,415,900,000 | ABBV |
| FY2015 | +$2,900,300,000 | ABBV |
| FY2014 | +$344,400,000 | ABBV |
| FY2013 | −$4,323,100,000 | LLY |
| FY2012 | −$4,223,400,000 | LLY |
| FY2011 | −$6,842,500,000 | LLY |
The higher-revenue side has changed between ABBV and LLY over this period. The gap has narrowed since the earliest year compared.
15 of 19 comparable fiscal years — a year missing data on either side is not counted.
12 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | −24.7 pp | LLY |
| FY2024 | −15.9 pp | LLY |
| FY2023 | −6.4 pp | LLY |
| FY2022 | −1.5 pp | LLY |
| FY2021 | +0.8 pp | ABBV |
| FY2020 | −15.1 pp | LLY |
| FY2019 | −13.6 pp | LLY |
| FY2018 | +2.3 pp | ABBV |
| FY2017 | +19.8 pp | ABBV |
| FY2016 | +10.3 pp | ABBV |
| FY2015 | +10.4 pp | ABBV |
| FY2014 | −3.3 pp | LLY |
The higher net margin has changed hands between ABBV and LLY over this period.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
LLY's net margin has been more volatile than ABBV's over the 12 comparable fiscal years — 9.7 percentage points of standard deviation against 6.4.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between ABBV and LLY over these 12 fiscal years — ABBV led in 5 and LLY in 7.
12 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
ABBV's return on equity has been more volatile than LLY's over the 8 comparable fiscal years — 45.0 percentage points of standard deviation against 30.3.
8 of 18 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between ABBV and LLY over these 8 fiscal years — ABBV led in 6 and LLY in 2.
8 of 18 comparable fiscal years — a year missing data on either side is not counted.